Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review

Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.

Data presented by Eli Lilly & Co. at the American Society of Clinical Oncology annual meeting on the CDK4/CDK6 inhibitor abemaciclib in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer could be strong enough to support an accelerated approval and position the drug for a faster showdown with Pfizer Inc.’s Ibrance (palbociclib).

Lilly believes abemaciclib has the potential to be a best-in-class drug in a powerful category because of its potent efficacy and the prospect of continuous dosing, but a high rate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By 

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from R&D